Chromatide, a provider of innovative polymer technologies designed to improve and enhance pharmaceutical and chemical production and processes, is pleased to announce the formation of a highly respected and experienced Scientific Advisory Board (SAB). Each member of the SAB has been involved in the pharmaceutical, biotechnology and chemistry sectors for over 25 years. This extensive knowledge, and additional external validation, will greatly enhance the Company’s already strong scientific foundation to further grow its Intellectual Property (IP) portfolio.
Chromatide’s primary business is to develop and licence IP to provide a range of technologies offering superior performance and cost savings to the pharmaceutical and chemical production industries.
Chromatide’s SAB comprises Dr. Brian Adger, who has spent over 30 years in the pharmaceutical, biotechnology and fine chemical sectors, Dr. Eric Atherton, with over 30 years background in peptide chemistry and Professor Nigel Slater from Cambridge University with over 25 years research into bioproduct manufacture in industrial and academic laboratories.
Commenting on the announcement, Clare Hildred, the CEO of Chromatide, said, “We are delighted to have established such an accomplished and knowledgeable SAB. The combination of skills and expertise Dr Adger, Dr Atherton and Professor Slater bring will help us to continue to drive the Company business forward by providing highly regarded, objective views of the IP we are developing. The additional backgrounds in industry that the SAB has in companies including Smith Kline French (now GlaxoSmithKline), Sterling Organics, Great Lakes Chemical Europe, Chiroscience, Avecia, Zeneca, ICI, Unilever and Wellcome will also ensure that our IP will be directed at commercial improvements of chemical and biomolecule manufacturing processes”.
For further information please contact: Chromatide Limited; Clare Hildred, Chief Executive Officer Officer; +44 (0)7710 387256; info@chromatide.com; www.chromatide.com
www.chromatide.com
